openPR Logo
Press release

Primary Sclerosing Cholangitis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Gilead, Immunic, CymaBay, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic

11-27-2023 05:51 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Primary Sclerosing Cholangitis Pipeline Analysis (2023)

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Primary Sclerosing Cholangitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Primary Sclerosing Cholangitis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Sclerosing Cholangitis Therapeutics Market.

The report provides a detailed description of the Primary Sclerosing Cholangitis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Primary Sclerosing Cholangitis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Sclerosing Cholangitis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Primary Sclerosing Cholangitis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Primary Sclerosing Cholangitis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Primary Sclerosing Cholangitis treatment market.

Learn More about the Clinical and Commercial Development Activities in the Primary Sclerosing Cholangitis Therapeutics Domain @
https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Sclerosing Cholangitis Therapeutics Analysis
High-dose ursodeoxycholic acid is used to treat PSC patients because of a trend toward increased survival. Dominant bile duct stenosis should be treated endoscopically. However, liver transplantation remains the only therapeutic option for patients with advanced disease.

Apart from this, Immunosuppressive-based therapies such as glucocorticoids, azathioprine, tacrolimus, and a few others are in use, especially in those patients with additional features of autoimmune hepatitis (AIH) or IgG4-related sclerosing cholangitis (IgG4-SC). Although they had shown improvements in liver biochemistry, these effects were not sustained and did not show clinical benefit. The outcomes were not assessed over prolonged periods to determine the progression to cirrhosis. This makes their inclusion in daily practice all the more difficult.

Antibiotics, such as vancomycin, metronidazole, and tetracycline, were investigated to assess the interrelationship between systemic and mucosal inflammation. However, limited evidence does not support vancomycin (or other antibiotics) for treating PSC liver disease without cholangitis. Several antimicrobial agents have been used and studied in treating PSC, including rifaximin, tetracycline, minocycline, metronidazole, and OVT, with mixed results.

Several major pharma and biotech companies are developing therapies for Primary Sclerosing Cholangitis. Currently, Gilead Sciences is leading the therapeutics market with its Primary Sclerosing Cholangitis drug candidates in the most advanced stage of clinical development.

Primary Sclerosing Cholangitis Companies in the Therapeutics Market Include:
• Gilead Sciences
• Immunic
• Dr Falk Pharma
• Pliant Therapeutics
• CymaBay Therapeutics
• SCOHIA PHARMA
• Albireo Pharma
• Sirnaomics
• Morphic Therapeutic
And Many Others

Emerging and Marketed Primary Sclerosing Cholangitis Therapies Covered in the Report Include:
• GS-9674: Gilead Sciences
• IMU-838: Immunic
• HTD 1801: HighTide Biopharma
• Norursodeoxycholic acid (norUDCA): Dr. Falk Pharma
And Many More

Get an in-depth Assessment of the Emerging Therapies and Primary Sclerosing Cholangitis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Primary Sclerosing Cholangitis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Primary Sclerosing Cholangitis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Primary Sclerosing Cholangitis Current Treatment Patterns
4. Primary Sclerosing Cholangitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Sclerosing Cholangitis Late-Stage Products (Phase-III)
7. Primary Sclerosing Cholangitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Sclerosing Cholangitis Discontinued Products
13. Primary Sclerosing Cholangitis Product Profiles
14. Primary Sclerosing Cholangitis Companies
15. Primary Sclerosing Cholangitis Drugs
16. Dormant and Discontinued Products
17. Primary Sclerosing Cholangitis Unmet Needs
18. Primary Sclerosing Cholangitis Future Perspectives
19. Primary Sclerosing Cholangitis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Acute Ocular Pain Market
https://www.delveinsight.com/report-store/acute-ocular-pain-market

Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market

Antibody-Mediated Graft Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-graft-rejection-market

Bacterial (Pyogenic) Meningitis Market
https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market

Bevacizumab Biosimilars
https://www.delveinsight.com/report-store/bevacizumab-biosimilars-insight

Bronchial Neoplasm Market
https://www.delveinsight.com/report-store/bronchial-neoplasm-market

Calcinosis Cutis Market
https://www.delveinsight.com/report-store/calcinosis-cutis-market

Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market

Dermal Regeneration Matrix Market
https://www.delveinsight.com/report-store/dermal-regeneration-matrix-market

Epstein Barr virus (EBV) Market
https://www.delveinsight.com/report-store/epstein-barr-virus-ebv-market

Glabellar Frown Lines Market
https://www.delveinsight.com/report-store/glabellar-frown-lines-market

Goitre Market
https://www.delveinsight.com/report-store/goitre-market

Hereditary Deafness Medical Device Market
https://www.delveinsight.com/report-store/hereditary-deafness-medical-devices-market

ICOS-Next Generation Immunotherapy Market
https://www.delveinsight.com/report-store/icos-next-generation-immunotherapy-competitive-landscape

Metrorrhagia Market
https://www.delveinsight.com/report-store/metrorrhagia-market

Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market

Parkinson's Disease Related Dementia Market
https://www.delveinsight.com/report-store/parkinsons-disease-related-dementia-market

Peripherally Inserted Central Catheter (PICC) Devices Market
https://www.delveinsight.com/report-store/peripherally-inserted-central-catheter-picc-devices-market

Severe Toxicities in Lymphoma Market
https://www.delveinsight.com/report-store/severe-toxicities-in-lymphoma

Single Ventricle Heart Disease Market
https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market

Small Fiber Neuropathy Market
https://www.delveinsight.com/report-store/small-fiber-neuropathy-market

Stuttering Market
https://www.delveinsight.com/report-store/stuttering-market

Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market

Hyperopia Market
https://www.delveinsight.com/report-store/hyperopia-market

Microvascular Angina Market
https://www.delveinsight.com/report-store/microvascular-angina-market

Progressive Familial Intrahepatic Cholestasis Market
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market

CRISPR Therapies Pipeline Insight
https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight

Endometrial Hyperplasia Market
https://www.delveinsight.com/report-store/endometrial-hyperplasia-market

Adenoid Cystic Carcinoma Market
https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market

Chronic Pain Associated with Painful Diabetic Neuropathy Market
https://www.delveinsight.com/report-store/chronic-pain-associated-with-painful-diabetic-neuropathy-market

Contact Dermatitis Market
https://www.delveinsight.com/report-store/contact-dermatitis-market

Dermal Mycosis Market
https://www.delveinsight.com/report-store/dermal-mycosis-market

High-Grade Glioma Market
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market

Lymphatic Malformations Market
https://www.delveinsight.com/report-store/lymphatic-malformations-market

Nocturnal Enuresis Market
https://www.delveinsight.com/report-store/nocturnal-enuresis-market

Ulcer Haemorrhage Market
https://www.delveinsight.com/report-store/ulcer-haemorrhage-market

Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market

Alcohol Use Disorder (AUD) Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market

Cell And Gene Therapy For Multiple Myeloma Market
https://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market

Chronic Pancreatitis (CP) Market
https://www.delveinsight.com/report-store/chronic-pancreatitis-market

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market

End-Stage Coronary Artery Disease Market
https://www.delveinsight.com/report-store/end-stage-coronary-artery-disease-market

Frontotemporal Dementia Market
https://www.delveinsight.com/report-store/frontotemporal-dementia-market

Cell and Gene Therapies in Rare Disorders Market
https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market

Glycogen Storage Disease Market
https://www.delveinsight.com/report-store/glycogen-storage-disease-market

Maple Syrup Urine Disease Market
https://www.delveinsight.com/report-store/maple-syrup-urine-disease-market

MELAS Syndrome Market
https://www.delveinsight.com/report-store/melas-syndrome-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Sclerosing Cholangitis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Gilead, Immunic, CymaBay, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic here

News-ID: 3305339 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Primary

Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031. Primary Biliary Cholangitis (PBC), formerly known as
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk